Loquacious-PD (Loqs-PD) is required for biogenesis of many endogenous siRNAs in Drosophila. In vitro, Loqs-PD enhances the rate of dsRNA cleavage by Dicer-2 and also enables processing of substrates normally refractory to cleavage. Using purified components, and Loqs-PD truncations, we provide a mechanistic basis for Loqs-PD functions. Our studies indicate that the 22 amino acids at the C terminus of Loqs-PD, including an FDF-like motif, directly interact with the Hel2 subdomain of Dicer-2's helicase domain. This interaction is RNA-independent, but we find that modulation of Dicer-2 cleavage also requires dsRNA binding by Loqs-PD. Furthermore, while the first dsRNA-binding motif of Loqs-PD is dispensable for enhancing cleavage of optimal substrates, it is essential for enhancing cleavage of suboptimal substrates. Finally, our studies define a previously unrecognized Dicer interaction interface and suggest that Loqs-PD is well positioned to recruit substrates into the helicase domain of Dicer-2.
T
here are two Dicer genes in Drosophila melanogaster, Dcr-1 and Dcr-2, that produce micro-RNAs (miRNAs) and short interfering RNAs (siRNAs), respectively (1, 2) . Dcr-2 is required to initiate antiviral RNA interference (RNAi), in which viral double-stranded RNA (dsRNA) is cleaved to produce siRNAs capable of silencing viral gene expression (3, 4) . In vitro studies indicate Dcr-2 recognizes dsRNA termini and exhibits terminidependent cleavage (5, 6) . For example, dsRNA with blunt (BLT) termini are cleaved processively in an ATP-dependent manner, while dsRNA with 2-nt 3′overhanging (3′ovr) termini elicit distributive cleavage that occurs in the absence of ATP. Dcr-2's helicase domain plays an important role in termini discrimination (5, 6) and is required to mount an antiviral response (7, 8) , suggesting that the termini preferences of Dcr-2 likely arose to distinguish between viral and cellular dsRNA.
Loquacious-PD (Loqs-PD), a dsRNA-binding protein (dsRBP), is required for the biogenesis of a subset of endogenous-siRNAs (endo-siRNAs) (9, 10) but is not required for antiviral RNAi (8) . Early studies found that endo-siRNAs map to dsRNA originating from convergent transcription, inverted repeats, and transposons (11) (12) (13) (14) (15) (16) . Given the sensitive termini dependence of Dcr-2, many endo-siRNA precursors are predicted to be poor substrates. We recently showed that, in vitro, Loqs-PD minimizes the termini dependence of Dcr-2 and facilitates cleavage of suboptimal substrates, including predicted endo-siRNA precursors (6) . This suggests Loqs-PD evolved to expand the range of Dcr-2 endogenous substrates; however, the mechanism by which Loqs-PD modulates Dcr-2 substrate recognition and processing is unknown.
Loqs-PD is one of four protein isoforms encoded by the gene loqs. Loqs-PA and Loqs-PB, homologs of TRBP, interact with Dcr-1 during miRNA biogenesis (9, (17) (18) (19) (20) . Loqs-PC is rarely expressed and has no known function (9) . Loqs-PD is the only Loqs isoform capable of facilitating Dcr-2-dependent endosiRNA biogenesis (19, 20) . It contains two dsRNA-binding motifs (dsRBMs) separated by a short linker, with the rest of the protein predicted to be largely unstructured. Only the C-terminal 22 amino acids are unique to the PD isoform ( Fig. 1 A and C) , and studies performed in S2 cells indicate they are important for endosiRNA silencing (21) and for interactions with Dcr-2 (21, 22) . However, studies monitoring the interaction between Loqs-PD and Dcr-2 by immunoprecipitation have noted varying degrees of association (9, 10, 23) , and so far, studies with purified proteins have not been performed. During RISC assembly, Dcr-2 interacts with another dsRBP, R2D2, and it is unclear whether R2D2 and Loqs-PD compete for the same binding site (23) or bind to unique sites (22) .
Using purified components, we performed a series of biochemical experiments to investigate the mechanism by which Loqs-PD modulates Dcr-2 activity. We show that Loqs-PD directly interacts with Dcr-2 in an RNA-independent manner, and this interaction, as well as Loqs-PD binding to dsRNA, are both required for Loqs-PD function. We discovered the first dsRBM of Loqs-PD is uniquely required to enhance cleavage of suboptimal substrates but not an optimal substrate. Finally, we report an unrecognized Dicer-dsRBP interaction interface and describe its potential implication for the function of Loqs-PD.
Results
Purification of Loqs-PD Truncations. We previously showed that Loqs-PD modifies Dcr-2 cleavage activity, but the mechanism by which Loqs-PD accomplishes this is unknown. To identify regions of Loqs-PD required to alter Dcr-2 activity, we designed and purified a series of N-and C-terminal truncations ( Fig. 1 A  and B) . By precedent (24) , each construct was named based on domains or features it contained. For example, the smallest construct, LR 2 C, contained the linker region between dsRBMs Significance Drosophila melanogaster use RNA interference to respond to a viral infection. Dicer-2 cleaves viral double-stranded RNA (dsRNA), producing siRNAs that silence viral gene expression. Dicer-2 recognizes the ends of dsRNA, and this property likely evolved to distinguish between viral and cellular dsRNA. Loquacious-PD (Loqs-PD), a dsRNA binding protein, is not required for Dicer-2's antiviral activity. However, by allowing Dicer-2 to cleave in a termini-independent manner, Loqs-PD facilitates cleavage of endogenous substrates with more complex termini. Our studies are significant because they provide a mechanistic basis for how Loqs-PD modulates Dicer-2 activity. For example, they reveal a previously unrecognized proteinprotein interaction interface on the helicase domain of Dicer-2.
(L), the second dsRBM (R 2 ), and the C-terminal tail (C), while the N-terminal region (N) and the first dsRBM (R 1 ) were deleted. NR 1 LR 2 C Δ22 lacked the C-terminal 22 amino acids, which are the only amino acids unique to the PD isoform (Fig. 1C) . While many dsRBPs form homodimers in solution (25) (26) (27) , Loqs-PD and all of its truncations were found to be monomers by sedimentation equilibrium experiments (Fig. S1 ).
Loqs-PD Requires the C-Terminal 22 Residues to Fully Enhance Dcr-2
Cleavage. To determine which domains of Loqs-PD were required to affect Dcr-2 cleavage activity in vitro, we performed single-turnover cleavage assays using dsRNAs with BLT or 3′ovr termini (created by annealing 106-nt sense and antisense RNAs), with Dcr-2 WT alone or supplemented with Loqs-PD or its truncations ( Fig. 2 A and B, Table 1 , and Fig. S2 ). As in our prior studies (6), Dcr-2 alone (-, dotted) cleaved 106 BLT dsRNA at a faster rate (k obs , 0.12 ± 0.02 min ), emphasizing that dsRNA with BLT termini is an optimal substrate compared with dsRNA with 3′ovr, or other non-BLT termini (suboptimal substrates). Inclusion of fulllength Loqs-PD (NR 1 LR 2 C, black lines) dramatically increased the rates of cleavage for both BLT (k obs , 1.98 ± 0.05 min −1 ) and 3′ovr (k obs , 0.73 ± 0.06 min −1 ) 106 dsRNA, and a similar rate enhancement was observed when the N-terminal 135 residues were removed (R 1 LR 2 C, green lines). Conversely, removal of the C-terminal 22 amino acids from Loqs-PD (NR 1 LR 2 C Δ22 , red lines) severely compromised the ability of Loqs-PD to stimulate Dcr-2 cleavage activity, for both BLT and 3′ovr dsRNA. Thus, the N terminus of Loqs-PD is dispensable for Loqs-PD effects on Dcr-2 cleavage, while the C-terminal 22 amino acids are essential.
Loqs-PD Requires both dsRBMs to Enhance Dcr-2 Cleavage of Suboptimal Substrates. Unexpectedly, additional truncation to remove the first dsRBM (LR 2 C, blue lines) revealed substrate-dependent effects. LR 2 C increased the Dcr-2 cleavage rate for 106 BLT dsRNA to levels approaching that observed after addition of full-length Loqs-PD (k obs , 1.28 ± 0.07 min −1 vs. k obs , 1.98 ± 0.05 min
−1
). However, while LR 2 C slightly increased the Dcr-2 cleavage rate for 106 3′ovr dsRNA, the rate was ∼fourfold slower than that observed in the presence of NR 1 LR 2 C (k obs , 0.19 ± 0.04 min −1 vs. k obs , 0.73 ± 0.06 min −1 ). To extend these results to a natural, endogenous substrate, we tested a dsRNA derived from esi-2, a Drosophila endosiRNA precursor that gives rise to abundant endo-siRNAs in vivo (13) (14) (15) . esi-2 contains 20 inverted repeats capable of forming multiple stem-loop, or hairpin, structures, and we used a substrate with a single inverted repeat flanked by noncomplementary sequences. This substrate, referred to as esi-2 hairpin (esi-2 hp ) [previously referred to as pre-sl by Miyoshi et al. (22) ], is predicted to form a single hairpin with single-stranded overhangs at each terminus (Fig. 2D, Bottom) . While the endogenous termini of esi-2 have not been defined, we previously showed that, in vitro, esi-2 hp recapitulates the Loqs-PD-dependent siRNA production (6) observed in vivo (9, 10) . We performed singleturnover cleavage assays of esi-2 hp with Dcr-2 WT alone, or supplemented with Loqs-PD or its truncations, in the presence (+) or absence (−) of ATP ( Fig. 2 C and D) . Dcr-2 alone was unable to appreciably cleave esi-2 hp , while addition of NR 1 LR 2 C resulted in cleavage and siRNA-sized cleavage products. As with the 3′ovr 106 dsRNA substrate, R 1 LR 2 C enhanced cleavage of esi-2 hp to the same extent as NR 1 LR 2 C, while NR 1 LR 2 C Δ22 and LR 2 C showed a significantly decreased ability to promote cleavage. All cleavage events were dependent on ATP (Fig. 2C) . Thus, while esi-2 hp differs from 3′ovr 106 dsRNA in that its cleavage is completely dependent on Loqs-PD, it is a suboptimal substrate and, like 3′ovr dsRNA, requires both dsRBMs for cleavage.
In addition to the siRNA-sized cleavage products of esi-2 hp , larger products of ∼33 and ∼43 nts accumulated in a Loqs-PDdependent manner (Fig. 2C) . In vivo, esi-2 is processed into two adjacent endo-siRNAs, esi-2.1 and esi-2.2, leaving the ∼42 nt loop region as a byproduct (14) (Fig. S3A ). To get information about the identity of bands observed in our in vitro cleavage assays, we performed Northern blots in which we probed for a region that encompasses esi-2.1 (nucleotides 30-60, red), the predominant endo-siRNA observed from esi-2 (13-15), the loop region (nucleotides 79-109, green), or the 3′ end of esi-2 hp (nucleotides 158-190, blue) (Fig. S3B) . The "red" probe primarily detected siRNA-sized products, suggesting that siRNAsized products in Fig. 2C include esi-2.1. The loop probe primarily detected ∼43 nt-sized products, suggesting the ∼43-nt band in Fig. 2C corresponds to the loop region of esi-2 hp . Finally, the 3′-end probe detected multiple bands, including likely intermediates, and an ∼33 nt product, suggesting the ∼33-nt band in Fig. 2C corresponds to the hairpin base. These data are consistent with cleavage of esi-2 hp to produce two siRNAs and byproducts that include the hairpin loop and base and agree with prior analyses of esi-2 processing in vivo (14) .
Loqs-PD and Its Truncations Bind dsRNA with High Affinity. To gain insight into the differential ability of the Loqs-PD truncations to enhance Dcr-2 cleavage activity, we measured their dsRNA binding affinity. We performed gel mobility shift assays with each Loqs-PD variant and 106 BLT dsRNA (Fig. 3) . NR 1 LR 2 C bound dsRNA with high affinity, exhibiting a K d of ∼9 nM (Table 1) . We observed two faint bands of slower mobility, but the majority of bound or shifted dsRNA appeared as a diffuse smear (Fig. 3A , Top Left), suggesting a subset of complexes dissociate during electrophoresis (28) . NR 1 LR 2 C Δ22 bound dsRNA with the same affinity as NR 1 LR 2 C (K d of ∼9 nM), and the pattern of shifted dsRNA was also similar (Fig. 3A , Top Right), indicating deletion of the 22 C-terminal amino acids does not compromise dsRNA binding. R 1 LR 2 C bound dsRNA with a slightly higher affinity (K d of ∼1.4 nM) than NR 1 LR 2 C, suggesting the N-terminal region is inhibitory to dsRNA binding. Further, there was a dramatic change in the pattern of shifted dsRNA. For R 1 LR 2 C, we observed the sequential appearance of ∼6 distinct complexes (Fig. 3A , Bottom Left), consistent with a maximal protein to dsRNA stoichiometry of 6:1. In structures with dsRNA, dsRBMs bind ∼16 bp along one face of the dsRNA helix such that another dsRBM can bind opposite the first (29, 30) . To accommodate six molecules of R 1 LR 2 C (∼32 bp) on a 106-bp substrate, we predict binding occurs along opposite faces of the dsRNA. LR 2 C bound dsRNA with slightly lower affinity (K d of ∼29 nM), consistent with the loss of one of the two dsRBMs. We observed one prominent shift along with a faint second shift. LR 2 C also exhibits a Hill coefficient >1, suggesting some form of cooperativity may be operative. As summarized in Fig. 3B , removal of the C-terminal 22 amino acids does not alter binding affinity from that of the full-length protein, while removal of the N terminus increases affinity and deletion of both the N terminus and first dsRBM decreases affinity. Previous studies suggest the C-terminal 22 residues of Loqs-PD are required to interact with Dcr-2 (21, 22) . However, the interaction has not been monitored with purified proteins. Whether Loqs-PD and Dcr-2 interact in the absence of RNA also is untested. To address these questions, we used purified proteins in pull-down experiments with His-tagged Loqs-PD variants and untagged Dcr-2. To facilitate formation of a stable complex, we used a Dcr-2 variant in which both RNaseIII and helicase activity were disrupted by point mutations (Dcr-2 RIII,K34A
). We Values shown are mean ± SEM (n = 3). n/a, not applicable; n.d., not determined.
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found that NR 1 LR 2 C was able to pull down Dcr-2 (Fig. 4A, lane 7) , confirming a direct interaction. Additionally, our recombinant proteins were free of RNA as measured by A 260/280 , suggesting this interaction is RNA-independent. By contrast, NR 1 LR 2 C Δ22 was unable to pull down Dcr-2 (Fig. 4A, lane 8) , confirming that the C terminus of Loqs-PD is required for a direct, RNA-independent interaction with Dcr-2. R 1 LR 2 C and LR 2 C were both able to pull down Dcr-2 ( Fig. 4A , lanes 9 and 10), although R 1 LR 2 C pulled down slightly less Dcr-2 that NR 1 LR 2 C or LR 2 C (Fig. 4B) . Thus, Loqs-PD directly binds Dcr-2, and its C-terminal 22 amino acids are required for this interaction.
To determine whether the C-terminal 22 residues of Loqs-PD alone were able to bind Dcr-2, we synthesized the 22-residue peptide (PD22) and performed a competition experiment in which we pulled down Dcr-2 with LR 2 C in the presence of increasing amounts of PD22 (Fig. 4 C and D) . PD22 effectively competed for binding with LR 2 C as seen by the dose-dependent decrease in the amount of Dcr-2 pulled down by LR 2 C (Fig. 4C , lanes 9-11 compared with lane 8). To control for nonspecific effects from the high concentration of peptide used, a mutated version of PD22 (PD22 mut , described below) was tested at the highest concentration of peptide assayed. PD22 mut did not compete for the interaction between LR 2 C and Dcr-2 (Fig. 4C,  lane 12) , confirming the specificity of the PD22 interaction. We attempted direct binding studies by fluorescence polarization using a fluorescein-labeled version of PD22 but were unable to saturate binding without using prohibitively high concentrations of Dcr-2. Without quantitative binding studies, we cannot rule out that other portions of Loqs-PD contribute to binding, but our analyses indicate the C-terminal 22 amino acids of Loqs-PD directly interact with Dcr-2.
dsRNA Binding Is Required by Loqs-PD to Affect Dcr-2 Cleavage Activity. Our cleavage assays with NR 1 LR 2 C Δ22 (Fig. 2) confirmed that the C-terminal 22 residues of Loqs-PD were essential for enhancing Dcr-2 cleavage activity. Our pull-downs (Fig. 4) provided an explanation in that those residues were required for interaction with Dcr-2. An outstanding question was whether dsRNA-binding by Loqs-PD was also required to enhance Dcr-2 cleavage activity. To test this, we disrupted dsRNA-binding activity of Loqs-PD in a construct capable of enhancing Dcr-2 activity. We selected LR 2 C because it contained a single dsRBM yet was able to enhance Dcr-2 activity toward a 106 BLT dsRNA to a similar extent as full-length Loqs-PD ( Fig. 2A) . dsRBMs contain a highly conserved KKxxK motif, which mediates direct interaction with the phosphate backbone of dsRNA (29) (30) (31) . To disrupt the dsRNA-binding activity of LR 2 C, we mutated lysine 301, present in the KKxxK motif of dsRBM2 ( Fig. 5 A and B) . We performed gel shift assays of 106 BLT dsRNA with His-LR 2 C or His-LR 2 C K,A (Fig. 5C ). Indeed, mutation of lysine 301 to alanine resulted in a ∼55-fold reduction in binding affinity by His-LR 2 C K,A compared with His-LR 2 C (Fig. 5D and Table 1 ). The presence of the 6xHis tag had no effect on dsRNA binding (K d ∼ 29 nM vs. K d ∼ 30 nM, respectively) ( Table 1) . To ensure that the decrease in dsRNA-binding affinity was due to the mutation and not a secondary affect of protein misfolding, we compared His-LR 2 C and His-LR 2 C K,A by circular dichroism (CD) spectroscopy (Fig. S4A) . CD spectra reflect the secondary structure composition of a protein (32) , and there was no significant difference between the His-LR 2 C and His-LR 2 C K,A spectra, suggesting the K301A mutation did not grossly affect protein folding. Thus, LR 2 C K,A was properly folded but had greatly reduced affinity for dsRNA.
We performed pull-downs with His-LR 2 C K,A and found that the dsRBM mutation had no effect on Dcr-2 binding (Fig. 5 E  and F) . This result emphasized that the interaction between Dcr-2 and Loqs-PD is independent of dsRNA. After determining that His-LR 2 C K,A had greatly reduced dsRNA-binding affinity but was still capable of interacting with Dcr-2, we tested whether His-LR 2 the conditions tested. In addition to the single point mutant, we made a more severe mutant in which all three lysines of the KKxxK motif were mutated to EAxxA (Fig. S4 B and C) . We obtained similar results for K,A and KKK,EAA mutants in all of the above experiments (Table 1 and Fig. S4 ). Thus, Loqs-PD must bind dsRNA as well as Dcr-2 to enhance Dcr-2 cleavage activity. When treated with DSS, Dcr-2 migrated slightly slower during SDS/PAGE (D vs. D+xl) (Fig. 6A, compare lanes 1 and 6) . Loqs-PD and its truncations migrated slightly faster after DSS treatment, with broader, more diffuse bands (L vs. L+xl; Fig. 6A , compare lanes 2-5 and 7-10). In both cases, the altered SDS/PAGE mobility is likely due to intraprotein cross-linking. When Dcr-2 was incubated with NR 1 LR 2 C and treated with DSS, the main Dcr-2 band (D+xl) shifted to a higher molecular mass species, suggesting formation of a covalent adduct between Loqs-PD and Dcr-2 (D+L+xl) (Fig. 6A, compare lanes 6 and 11) . Consistent with the requirement of the C-terminal 22 amino acids for interacting with Dcr-2 in pull-down assays (Fig. 4 A and B) , the D+L+xl species was greatly reduced when cross-linking was performed with NR 1 LR 2 C Δ22 (Fig. 6A, compare lanes 11 and 12) . Cross-linking performed with Dcr-2 and R 1 LR 2 C or LR 2 C also resulted in the D+L+xl species (Fig. 6A, lanes 13 and 14) . The agreement between our cross-linking and pull-downs suggests DSS cross-linking captures the native interaction between Loqs-PD and Dcr-2.
To identify the sites of cross-linking between Dcr-2 and Loqs-PD, we analyzed the in-gel tryptic digest of the D+L+xl species by LC-MS/MS. We identified peptides mapping to both Dcr-2
Input His-tag Pull-down and Loqs-PD (Table S1) , suggesting the second shift we observed by SDS/PAGE was indeed due to Loqs-PD cross-linking to Dcr-2. We identified 18 Dcr-2-Dcr-2 cross-links and one Dcr-2-Loqs-PD cross-link from two replicates (Fig. 6B and Table S2 ). The sole Loqs-PD-Dcr-2 cross-link and 11/18 Dcr-2-Dcr-2 crosslinks were identified in both replicates. We predict all identified Dcr-2-Dcr-2 cross-linked peptides reflect intraprotein rather than interprotein cross-linking because the difference in SDS/PAGE mobility between untreated (D) and treated (D+xl and D+L+xl) samples was very slight. In samples treated with DSS, some protein remained trapped in the wells and may correspond to Dcr-2-Dcr-2 interprotein cross-links that were too large to enter the gel. The sole interprotein cross-link was between the penultimate residue of Loqs-PD, K358, and K501 in Dcr-2, which is located in the Hel2 subdomain of the helicase domain. As a control, we analyzed the in-gel tryptic digest of the D+xl species by LC-MS/MS and identified 16 Dcr-2-Dcr-2 cross-links, and no cross-linked peptides corresponding to Loqs-PD, in two replicates. Nine of 16 Dcr-2-Dcr-2 cross-links were identified in both replicates. Given that the Loqs-PD-Dcr-2 cross-link occurs in the C-terminal 22 residues of Loqs-PD, which are required for interaction with Dcr-2, we predict the reciprocal site of cross-linking in Dcr-2 correctly identifies the interaction surface, Hel2.
Loqs-PD Interacts with Dcr-2 Through an FDF-Like Motif. DSS contains an eight-carbon linker (11.4 Å) between reactive NHS-ester moieties. When cross-linking occurs between lysine side chains, the alpha carbons of each lysine should be within ∼24 Å [Lys1 (6.4 Å)-DSS(11.4 Å)-Lys2(6.4 Å)] (37). To verify the specificity of cross-linking, we determined how many of the identified crosslinks met this distance constraint. Since the only identified interprotein cross-link to Loqs-PD was in the helicase domain of Dcr-2, we focused analyses on the helicase domain. There are no high-resolution structures available for a Dicer helicase domain, but there are structures available for related helicases from the RIG-I-like and DEAD-box families. We generated a homology model of Dcr-2's helicase domain using Robetta (38) (robetta. bakerlab.org) (Fig. 6C) . From our combined XL-MS data, we identified seven intraprotein cross-links within the helicase domain. Using our homology model, we measured the distance between alpha carbons of cross-linked residues and found that 7/7 were within 24 Å (Fig. S5A) ; this suggests our homology model is accurate and that we are detecting structurally plausible cross-links.
We were unable to find documented examples of proteinprotein interactions mediated by Hel2 for other RIG-I-like helicases, so we expanded our search to the closely related DEAD-box helicase family (39) . DDX6, a DEAD-box helicase involved in mRNA decapping and degradation, interacts with several proteins via its second RecA motif (DDX6-C) (40) , which is analogous to Hel2 in Dcr-2. DDX6-C-interacting proteins, such as EDC3, typically bind DDX6 through short peptide interactions involving a Phe-Asp-Phe sequence, known as an FDF motif (40) (41) (42) (Fig. 6D, Bottom) . In a crystal structure of DDX6-C and a peptide derived from EDC3 (EDC3-FDF), the two phenylalanines of the FDF motif in EDC3 pack into a hydrophobic pocket on the surface of DDX6-C, distal from the RNA-and ATP-binding sites of DDX6 (43) (Fig. 6D, Left) . Interestingly, Loqs-PD contains a putative FDF-like motif in its C-terminal 22 amino acids (Fig. 6D, Bottom) , raising the possibility that Loqs-PD binds Dcr-2 in a manner analogous to EDC3-FDF and DDX6-C.
We structurally aligned Hel2 of our Dcr-2 helicase model with DDX6-C and noticed that the peptide we identified as crosslinking to Loqs-PD (shown in blue), while not superimposable, was in close proximity to the EDC3-FDF binding site in DDX6-C (Fig. 6D, Right) . To determine if the FDF-like motif of Loqs-PD could bind Dcr-2 similarly to the DDX6-C-EDC3-FDF interaction, we measured the distance between K501 in Dcr-2 and residues in EDC3-FDF that would correspond to K358 of Loqs-PD in either orientation. Both distances were <24 Å, consistent with the distance constraints of DSS cross-linking (Fig.  S5B) . Beyond the FDF-like motif, Loqs-PD and EDC3 have low sequence similarity, and thus, we cannot confidently predict other interactions, or the orientation of Loqs-PD, from the DDX6-C-EDC3-FDF crystal structure.
While additional studies are required to elucidate the detailed interface, our XL-MS data and comparative modeling suggest Loqs-PD interacts with Hel2 of Dcr-2 using a putative FDF-like motif. To directly test this hypothesis, we mutated both phenylalanines in the FDF-like motif of full-length Loqs-PD to alanines (Fig. S6 A and B) . We performed pull-downs of Dcr-2 with Histagged Loqs-PD constructs, including the FDF-like motif mutant NR 1 LR 2 C FF,AA ( Fig. 6 E and F) . Mutation of the FDF-like motif reduced the interaction between Dcr-2 and NR 1 LR 2 C FF,AA (compare lanes 6 and 7) to the same extent as deleting the C-terminal 22 residues (compare lanes 7 and 8). This suggests the FDFlike motif in the C-terminal tail of Loqs-PD is required for interaction with Dcr-2. We performed gel shift assays with NR 1 LR 2 C FF,AA and saw no difference in dsRNA-binding affinity compared with NR 1 LR 2 C, suggesting that protein folding has not been grossly perturbed (Table 1 and Fig. S6 C and  D) . Finally, we compared the ability of the FDF-like motif mutant (NR 1 LR 2 C FF,AA ) to promote cleavage of esi-2 hp to that of either wild-type Loqs-PD (NR 1 LR 2 C) or the Loqs-PD construct lacking the C-terminal 22 amino acids (NR 1 LR 2 C Δ22 ) (Fig.  S6 E and F) . Mutation of the FDF-like motif completely abolished the ability of Loqs-PD to enhance cleavage of esi-2 hp and is comparable to entirely removing the C-terminal 22 amino acids. Thus, the isoform-specific C terminus of Loqs-PD contains an FDF-like motif that is required for direct interaction with Dcr-2 and to promote cleavage of a suboptimal substrate.
Discussion
Since its discovery, Loqs-PD has been implicated in endo-siRNA biogenesis, but a detailed mechanistic understanding of its function is lacking. Based on our prior study (6) and the biochemical experiments presented here, we propose an integrated model for Loqs-PD function in Dcr-2-dependent siRNA biogenesis (Fig. 7) .
In our model, Loqs-PD and Dcr-2 directly interact in the absence of dsRNA (Fig. 7A) , consistent with our pull-down and cross-linking data (Figs. 4 A and B , 5 E and F, and 6A). Based on our XL-MS data and subsequent mutational analysis (Fig. 6) , the interaction is mediated by an FDF-like motif in the isoformspecific C terminus of Loqs-PD and Hel2 of the Dcr-2 helicase domain. Results from our cleavage assays with NR 1 LR 2 C Δ22 (Fig. 2) confirm the necessity of the C-terminal 22 residues for Loqs-PD to fully enhance Dcr-2 cleavage toward both optimal and suboptimal substrates. We predict the defect results solely from an inability of NR 1 LR 2 C Δ22 to interact with Dcr-2 ( Fig. 4 A  and B) as NR 1 LR 2 C Δ22 had unaltered dsRNA binding compared with NR 1 LR 2 C (Fig. 3) . Based on these data, in Fig. 7 we depict the C-terminal 22 amino acids of Loqs-PD, including the FDFlike motif, interacting with Hel2 of Dcr-2 in all conditions and propose it is necessary for Loqs-PD function. Based on our homology model and structures of RNA-bound RIG-I-like helicases (44-48), we predict Loqs-PD is positioned such that it would pull a dsRNA into the C-shaped helicase domain of Dcr-2 ( Fig. 7B ) and that this positioning is critical to its function (see below).
In Fig. 7C , we depict the dsRNA-Dcr-2 complex in different conformations for optimal vs. suboptimal substrates, reflecting the intrinsic termini preference of Dcr-2 (6). In the presence of ATP and an optimal substrate (e.g., BLT dsRNA), Dcr-2 is proposed to undergo a conformational change in which the helicase domain clamps onto the dsRNA (closed conformation) to hold it along the body of the enzyme, which in turn promotes processive cleavage (Fig. 7C, Top Left) . the dsRNA positioned outside of the helicase domain, thus favoring distributive cleavage (Fig. 7C, Top Right) . Based on the experiments reported here, we predict the substrate-dependent conformations of the dsRNA-Dcr-2 complex dictate which domains of Loqs-PD are required to enhance cleavage. For an optimal substrate, either R 1 LR 2 C or LR 2 C is sufficient to enhance Dcr-2 cleavage ( Figs. 2A and 7C, Left) . In Fig. 7C , Bottom, R 1 LR 2 C/LR 2 C is shown interacting with Dcr-2 and the dsRNA substrate, consistent with our findings that dsRNA binding (Fig. 5) and Dcr-2 binding (Figs. 2 and 4 A and B) are both necessary for Loqs-PD to affect Dcr-2 activity. For an optimal substrate, we predict the dsRNA-Dcr-2 complex is in the closed conformation, which based on crystal structures of RNAbound RIG-I-like helicases (44) (45) (46) (47) (48) would position the dsRNA and Hel2 in close proximity such that LR 2 C is sufficient to simultaneously bind both. Thus, we depict LR 2 C (highlighted as solid lines in Fig. 7C, Bottom) holding the dsRNA in the correct orientation relative to the helicase domain to stabilize the closed conformation of the dsRNA-Dcr-2 complex.
For suboptimal substrates, in contrast, R 1 LR 2 C is the only variant sufficient to fully enhance Dcr-2 cleavage (Figs. 2 B-D and 7C, Right). For a suboptimal substrate, we predict the dsRNA-Dcr-2 complex is predominantly in an open conformation, which based on low-resolution cryo-EM reconstructions of human Dicer bound to an siRNA (49) may position the dsRNA and Hel2 farther apart such that LR 2 C is no longer sufficient to simultaneously bind both (Fig. 7C, Top Right) . This model is consistent with our findings that LR 2 C interacted with Dcr-2 comparable to full-length Loqs-PD (Fig. 4 A and B) and bound dsRNA (Fig. 3) yet was not sufficient to fully enhance cleavage of suboptimal substrates (Fig. 2 B-D) . Given that LR 2 C leads to a partial increase in cleavage of suboptimal substrates compared with NR 1 LR 2 C, we hypothesize that Dcr-2 occasionally transitions into the closed conformation (Fig. 7C , dashed arrow) such that LR 2 C can stabilize it to promote cleavage. In our model, inclusion of the first dsRBM extends the reach of R 1 LR 2 C, allowing it to now simultaneously bind both Dcr-2 and the dsRNA substrate. We predict this allows R 1 LR 2 C to reposition the substrate within the helicase domain of Dcr-2 such that it can now adopt the closed conformation and be stabilized by LR 2 C (Fig. 7C, Bottom) . Additional studies are needed to fully elucidate the structures and dynamics of the different conformations discussed.
As a general mechanism, we propose Loqs-PD coordinates Dcr-2 binding with dsRNA binding to promote or stabilize a conformational change in the helicase domain of Dcr-2, which correlates with increased cleavage. Consistent with this model, Loqs-PD has no effect in the absence of ATP (6) (Fig. 2C) , which we predict is required for the conformational change in Dcr-2. In vivo, under ATP-replete conditions, we expect Loqs-PD directly facilitates endo-siRNA biogenesis by this mechanism, although we cannot rule out the possibility that other factors may further enhance the efficiency.
Many of the annotated Dicer-dsRBP interactions require the helicase domain of Dicer (50, 51) , but the exact interface is unknown, with the exception of human TRBP and Dicer. Biochemical and structural studies indicate the third dsRBM of TRBP interacts with Hel2i of Dicer (52, 53) . A recent study suggests this interaction is conserved in the fly homologs Dcr-1 and Loqs-PB (20) . In contrast, our data indicate that Loqs-PD primarily interacts with Hel2 of Dcr-2's helicase (Fig. 6) , identifying an additional Dicer-dsRBP interaction interface. There are conflicting reports as to whether Loqs-PD and R2D2 simultaneously interact with Dcr-2 (22) or whether their binding is mutually exclusive (21, 23) . Additional studies are required to determine whether R2D2 binds the same Hel2 interface we have described for Loqs-PD or interacts with Hel2i of Dcr-2 in a manner analogous to TRBP and Dicer. It remains to be seen if other ATP-dependent Dicers such as Schizosaccharomyces pombe Dcr1 and Caenorhabditis elegans DCR-1 interact with dsRBPs similarly to Dcr-2 and Loqs-PD. Protein-protein interactions mediated by small motifs located in disordered regions have become a dominant theme among RNP assemblies (40, 54) .
Materials and Methods
Protein Expression and Purification. Loqs-PD and Dcr-2 were purified from Escherichia coli and Sf9 cells, respectively, as described (6) (SI Materials and Methods).
Synthesis of PD22 Peptide. PD22 and PD22 mut peptides were chemically synthesized as described (55) In Vitro Transcription of RNA Substrates. We prepared 106 dsRNA as described (6) . In the plasmid, each RNA strand was flanked by a hammerhead (5′ side) and HDV (3′ side) ribozyme to ensure accurate termini. 32 P-end-labeled 106 sense RNA was annealed with 106 BLT or 3′ovr antisense RNA to generate 106 BLT and 106 3′ovr dsRNA, respectively. esi-2 hp was cloned into the same ribozyme plasmid and prepared as described for 106 dsRNA with minor changes (see SI Materials and Methods for details). Sequences of 106 dsRNAs and esi-2 hp are in SI Materials and Methods.
Gel Shift and Cleavage Assays. Gel shift and single-turnover cleavage assays were performed as described (6) with minor changes (see SI Materials and Methods for details).
Pull-Down Assays. Dcr-2 RIII,K34A (2 μM) and His-Loqs-PD (4 μM) were incubated together in pull-down buffer (25 mM Tris, pH 8, 175 mM KCl, 10 mM MgCl 2 , 10 mM imidazole, 1 mM TCEP, 5% glycerol, 0.1% nonidet P-40) for 1 h at 4°C and added to prewashed His-Select Resin (Sigma-Aldrich) for 2 h at 4°C. Resin and bound proteins were pelleted by centrifugation, and unbound protein (supernatant) was removed. Resin was washed with chilled pulldown buffer, and bound protein was eluted in pull-down buffer containing 300 mM imidazole. Proteins were resolved on a 4-15% gradient gel and stained with Coomassie Brilliant Blue. Competition pull-down assays were performed as described above with addition of PD22 (10, 20, and 40 μM) or PD22 mut (40 μM) . Bound proteins were resolved on a 4-20% gradient gel by SDS/PAGE.
Chemical Cross-Linking. Dcr-2 RIII,K34A or OSF-Dcr-2 RIII , and Loqs-PD and its truncations, were dialyzed into cross-linking buffer (20 mM Hepes, pH 7.8, 100 mM KCl, 10 mM MgCl 2 , 1 mM TCEP, 5% glycerol). Cross-linking reactions were assembled with Dcr-2 (2 μM) and/or Loqs-PD (4 μM) and incubated (25°C, 30 min). DSS (5 mM in DMSO; Sigma-Aldrich) was added to make 100-400 μM final, and cross-linking was quenched after an additional 30 min at 25°C with 30 mM Tris, pH 8. Cross-linked proteins were resolved by SDS/ PAGE (4-15%) and detected with Coomassie Brilliant Blue.
MS and Identification of Cross-Linked Peptides. Bands corresponding to D+L+xl and D+xl were excised and subjected to in-gel digestion by trypsin and Lys-C. Peptides were extracted, reduced, treated with iodoacetamide, and analyzed using a nano-LC-MS/MS system equipped with a nano-HPLC pump (2D-ultra; Eksigent) and a maXis II ETD mass spectrometer (Bruker Daltonics). The maXis II ETD mass spectrometer was equipped with a captive spray ion source. Cross-linked peptides were identified using the webserver version of ProteinProspector2 (v5.18.0/1) (prospector.ucsf.edu/prospector/mshome.htm). A custom database was made containing amino acid sequences of Dcr-2 RIII,K34A or OSF-Dcr-2 RIII , His-Loqs-PD, and 20 decoy proteins. Loqs-PD and Dcr-2 sequences were each randomized 10 times using Decoy Database Builder (56) to generate decoy targets. Up to three missed cleavages were allowed. The MS1 and MS2 mass tolerances were both set to 11 ppm. DSS was specified as the cross-linker. Spectra were annotated as potential cross-linked products if the ProteinProspector total cross-linked product score was >20, and the score difference was >0. To identify high-confidence cross-link products (57), a score difference >8.5 was used, and spectra were manually verified.
Homology Modeling. A homology model of the Dcr-2 helicase domain (residues 1-539) was generated using the Robetta webserver (robetta.bakerlab. org); reference parent structure was DDX3X [Protein Data Bank (PDB) ID code 4PXA].
